Preoperative low skeletal muscle volume can result in insufficient administration of S-1 adjuvant chemotherapy in older patients with stage II/III gastric cancer

被引:1
|
作者
Kono, Yusuke [1 ]
Matsunaga, Tomoyuki [1 ]
Makinoya, Masahiro [1 ]
Shimizu, Shota [1 ]
Shishido, Yuji [1 ]
Miyatani, Kozo [1 ]
Kihara, Kyoichi [1 ]
Yamamoto, Manabu [1 ]
Takano, Shuichi [1 ]
Tokuyasu, Naruo [1 ]
Sakamoto, Teruhisa [1 ]
Hasegawa, Toshimichi [1 ]
Fujiwara, Yoshiyuki [1 ]
机构
[1] Tottori Univ, Sch Med, Dept Surg, Div Surg Oncol,Fac Med, 36-1 Nishi Cho, Yonago 6838504, Japan
关键词
Gastric cancer; Adjuvant chemotherapy; Sarcopenia; Elderly; S-1; ANAMORELIN;
D O I
10.1007/s00595-023-02737-2
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background and purposeOlder patients are more likely to encounter difficulties receiving chemotherapy, but the factors involved in the continuation of chemotherapy in these patients remain unclear. We investigated the importance of muscle mass as a factor involved in delivering a sufficient dose of postoperative S-1 adjuvant chemotherapy (ACT) to older patients with gastric cancer.MethodsThe subjects of this study were 79 patients aged & GE; 65 years with stage II/III gastric adenocarcinoma, who underwent curative gastrectomy and received S-1 ACT.ResultsThe overall median relative dose intensity (RDI) was 75.0% (18.8-93.5%). Patients were divided into two groups for receiver operating characteristic analysis according to the cutoff value. Significantly more patients in the high skeletal muscle index (SMI) group achieved > 62% RDI of S-1 ACT (p = 0.03). Conversely, more patients in the low SMI group suffered from S-1-induced nausea (p = 0.03) and discontinued chemotherapy because of adverse events (p = 0.02). Multivariate analysis identified low SMI as an independent factor for insufficient S-1 dose delivery (p = 0.03, hazard ratio = 2.87).ConclusionPreoperative SMI is an indicator of the low-dose intensity of S-1 ACT in older patients following curative gastrectomy.
引用
收藏
页码:340 / 346
页数:7
相关论文
共 50 条
  • [21] The efficacy of adjuvant chemotherapy for older adults with stage II/III gastric cancer: a retrospective cohort study
    Yu-Hsuan Shih
    Hsin-Chen Lin
    Po-Wei Liao
    Cheng-Wei Chou
    Cheng-Hsien Lin
    Chiann-Yi Hsu
    Chieh-Lin Jerry Teng
    Feng-Hsu Wu
    Shao-Ciao Luo
    Shao-Hsuan Kao
    BMC Cancer, 23 (1)
  • [22] Risk Factors for Peritoneal Recurrence in Stage II/III Gastric Cancer Patients Who Received S-1 Adjuvant Chemotherapy After D2 Gastrectomy
    Toru Aoyama
    Takaki Yoshikawa
    Tsutomu Hayashi
    Hiroshi Kuwabara
    Yo Mikayama
    Takashi Ogata
    Haruhiko Cho
    Akira Tsuburaya
    Annals of Surgical Oncology, 2012, 19 : 1568 - 1574
  • [23] Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy
    Shitara, Kohei
    Chin, Keisho
    Yoshikawa, Takaki
    Katai, Hitoshi
    Terashima, Masanori
    Ito, Seiji
    Hirao, Motohiro
    Yoshida, Kazuhiro
    Oki, Eiji
    Sasako, Mitsuru
    Emi, Yasunori
    Tsujinaka, Toshimasa
    GASTRIC CANCER, 2017, 20 (01) : 175 - 181
  • [24] Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol
    Namikawa, Tsutomu
    Maeda, Hiromichi
    Kitagawa, Hiroyuki
    Oba, Koji
    Tsuji, Akihito
    Yoshikawa, Takaki
    Kobayashi, Michiya
    Hanazaki, Kazuhiro
    BMC CANCER, 2018, 18
  • [25] Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol
    Tsutomu Namikawa
    Hiromichi Maeda
    Hiroyuki Kitagawa
    Koji Oba
    Akihito Tsuji
    Takaki Yoshikawa
    Michiya Kobayashi
    Kazuhiro Hanazaki
    BMC Cancer, 18
  • [26] Prediction of S-1 adjuvant chemotherapy benefit in Stage II/III gastric cancer treatment based on comprehensive gene expression analysis
    Nakamura, Kenichi
    Hatakeyama, Keiichi
    Furukawa, Kenichiro
    Fujiya, Keiichi
    Kamiya, Satoshi
    Hikage, Makoto
    Tanizawa, Yutaka
    Bando, Etsuro
    Ohshima, Keiichi
    Urakami, Kenichi
    Machida, Nozomu
    Yasui, Hirofumi
    Yamaguchi, Ken
    Terashima, Masanori
    GASTRIC CANCER, 2020, 23 (04) : 648 - 658
  • [27] Preoperative S-1 and docetaxel combination chemotherapy in patients with locally advanced gastric cancer
    Kosaka, Takashi
    Akiyama, Hirotoshi
    Makino, Hirochika
    Takagawa, Ryo
    Kimura, Jun
    Ono, Hidetaka
    Kunisaki, Chikara
    Endo, Itaru
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (02) : 281 - 285
  • [28] Prediction of S-1 adjuvant chemotherapy benefit in Stage II/III gastric cancer treatment based on comprehensive gene expression analysis
    Kenichi Nakamura
    Keiichi Hatakeyama
    Kenichiro Furukawa
    Keiichi Fujiya
    Satoshi Kamiya
    Makoto Hikage
    Yutaka Tanizawa
    Etsuro Bando
    Keiichi Ohshima
    Kenichi Urakami
    Nozomu Machida
    Hirofumi Yasui
    Ken Yamaguchi
    Masanori Terashima
    Gastric Cancer, 2020, 23 : 648 - 658
  • [29] Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy
    Kohei Shitara
    Keisho Chin
    Takaki Yoshikawa
    Hitoshi Katai
    Masanori Terashima
    Seiji Ito
    Motohiro Hirao
    Kazuhiro Yoshida
    Eiji Oki
    Mitsuru Sasako
    Yasunori Emi
    Toshimasa Tsujinaka
    Gastric Cancer, 2017, 20 : 175 - 181
  • [30] A phase III trial to confirm modified S-1 adjuvant chemotherapy for pathological stage II/III vulnerable elderly gastric cancer patients who underwent gastric resection (JCOG1507, BIRDIE)
    Mizutani, Tomonori
    Yamaguchi, Kazuya
    Mizusawa, Junki
    Ito, Seiji
    Nishida, Yasunori
    Yabusaki, Hiroshi
    Boku, Narikazu
    Sano, Takeshi
    Yoshida, Kazuhiro
    Sasako, Mitsuru
    Yoshikawa, Takaki
    Terashima, Masanori
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (12) : 1101 - 1104